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Abstract
People with Type 1 diabetes (T1D) require regular ex-
ogenous infusion of insulin to maintain their blood glu-
cose concentration in a therapeutically adequate tar-
get range. Although the artificial pancreas and contin-
uous glucose monitoring have been proven to be effec-
tive in achieving closed-loop control, significant chal-
lenges still remain due to the high complexity of glu-
cose dynamics and limitations in the technology. In this
work, we propose a novel deep reinforcement learning
model for single-hormone (insulin) and dual-hormone
(insulin and glucagon) delivery. In particular, the de-
livery strategies are developed by double Q-learning
with dilated recurrent neural networks. For designing
and testing purposes, the FDA-accepted UVA/Padova
Type 1 simulator was employed. First, we performed
long-term generalized training to obtain a population
model. Then, this model was personalized with a small
data-set of subject-specific data. In silico results show
that the single and dual-hormone delivery strategies
achieve good glucose control when compared to a stan-
dard basal-bolus therapy with low-glucose insulin sus-
pension. Specifically, in the adult cohort (n=10), per-
centage time in target range [70, 180] mg/dL improved
from 77.6% to 80.9% with single-hormone control, and
to 85.6% with dual-hormone control. In the adolescent
cohort (n=10), percentage time in target range improved
from 55.5% to 65.9% with single-hormone control, and
to 78.8% with dual-hormone control. In all scenarios,
a significant decrease in hypoglycemia was observed.
These results show that the use of deep reinforcement
learning is a viable approach for closed-loop glucose
control in T1D.
*The work was supported by EPSRC EP/P00993X/1, names with
∗ have equal contribution. The paper is under review.
1 Introduction
Diabetes is a chronic disease which affects millions of
people worldwide. It is characterised by elevated blood
glucose (BG) which in the long term can lead to com-
plications such as cardiovascular disease, retinopathy
and nephropathy. Its global prevalence rate has reached
epidemic proportions, doubling in the last 20 years [1].
There are two main types of diabetes, Type 1 and Type
2. Type 2 diabetes is characterised by the body inef-
fectively using insulin and can be usually treated with
lifestyle interventions and oral medication. Type 1 dia-
betes (T1D) however is distinguished by insufficient in-
sulin production by the pancreatic β-cell and therefore
requires exogenous insulin administration. The stan-
dard insulin replacement therapy for T1D includes a bo-
lus of fast-acting insulin to compensate the fast glucose
increase after meal ingestion, and a basal insulin deliv-
ery through an injection of slow-acting insulin to keep
glucose levels within target range in fasting conditions.
Alternatively, basal insulin can be delivered through
continuous infusion using an insulin pump with fast-
acting insulin. Although software tools such as bolus
calculators exist to support people with T1D to self-
administer insulin, they still fall short to achieve optimal
glycemic control [2]. Therefore, realising an automated
system to deliver optimal insulin doses is one of the
long-standing challenges in glucose management over
the past decades [3].
Recent improvements in accuracy and reliability of
continuous glucose monitoring (CGM) systems has al-
lowed the development of a closed-loop insulin deliv-
ery system, also known as the artificial pancreas (AP),
to automatically control BG levels in T1D [4]. An AP
consists of, at least, a CGM sensor, a control algorithm,
and an insulin pump. Additionally, some AP systems
might also incorporate a glucagon pump to counter-
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regulate the action of insulin [5] and an activity mon-
itor to quantify physical exercise [6]. Glucose measure-
ments are captured by the CGM device every five min-
utes and are sent to the control algorithm which calcu-
lates the corresponding dose of insulin aiming at main-
taining glucose level in a target range, which is then
delivered by the infusion device. To date, most existing
AP approaches that have been evaluated in clinic have
used a control engineering approach [7], and one uses
artificial intelligence (fuzzy logic) [8]. In particular, two
of them, the Medtronic 670G and the Tandem Control-
IQ have reached the commercialisation stage. However,
although these systems have been proven to improve
glycemic control [9,10], challenges remain, and further
work is needed to achieve optimal therapeutic targets.
In recent years, powered by the large scale of avail-
able medical data and the rapid advances in computa-
tional power, machine learning, in particular deep learn-
ing, has increasingly been used in many healthcare ap-
plications that were out of reach in the past [11], espe-
cially in diagnostics and medical imaging [12, 13].
In the field of diabetes, the use of machine lean-
ing has also attracted significant attention [14]. In
particular, neural networks (NN) have achieved suc-
cess in glucose forecasting [15] (fully-connected neu-
ral networks), [16, 17] (convolutional neural networks),
[18–20] (recurrent neural networks (RNN)), and [21]
(physiological-based networks). Of note, dilated RNN
(DRNN) has performed particularly well in process-
ing long-term dependencies and future glucose pre-
diction [18, 20, 22]. Recently, another technique under
the spotlight in the field of automatic insulin delivery
is reinforcement learning (RL) [23]. RL is a machine
learning framework for learning sequential decision-
making tasks. Many healthcare problems, such as drug
delivery, can be seen as closed-loop sequential action-
selection problems, which is what RL focuses on [24].
Unfortunately, the use of deep RL in healthcare has
been limited by several practical issues. Unlike success-
ful deep RL applications in the virtual world, such as
Atari video-games or board-game Go [24, 25] where
an agent dynamically interacts with a virtual environ-
ment, performing such exploration on human subjects
can be dangerous without proper safety constraints. Al-
ternatively, deep RL algorithms can learn from exist-
ing collected data using experience replay. This pro-
cess is called off-policy learning and plays an impor-
tant role in practical RL algorithms. However, collect-
ing the training data required is expensive and time con-
suming [26]. Fortunately, an FDA-accepted T1D simu-
lator developed in collaboration between the University
of Virginia (US) and the University of Padova (Italy)
is available for developing and evaluating insulin and
glucagon delivery strategies [27].
In this paper, we explore, in silico, the use of deep
RL for closed-loop control of BG levels in T1D. The
paper is organized as follows. Section 2 describes the
architecture and algorithms of the proposed deep RL
framework for glucose control. The performance of the
proposed method is evaluated in Section 3. Section 4
compares the results with existing work and discusses
the future work. Finally, we summarize the work in Sec-
tion 5.
2 Methodology
In this section, we state the problem of basal blood glu-
cose closed-control in terms of deep RL. Then, we in-
troduce a two-step framework, adapted from transfer
learning, to develop, in silico, single and dual-hormone
glucose controllers to be potentially used in clinical
practice.
In particular, a deep Q-learning model [24] is em-
ployed to optimize insulin and glucagon delivery. In-
sulin and glucagon dose deliveries are treated as actions
(a) taken by a stochastic policy, glycemic outcomes
(e.g. percentage time in glucose target) are considered
as rewards (r), and physiological variables are seen as
states (s). A deep neural network (DNN) is used as
a non-linear function approximator to estimate action-
values, also referred to as a deep Q-network (DQN).
Unlike previous methods to control AP systems using
conventional RL, no prior knowledge of the glucose-
insulin-glucagon metabolism is needed. Instead, a stack
of dilated recurrent layers is used for processing multi-
dimensional time series data. Because of its enlarged
receptive field, it is able to capture the complexity of
glucose-insulin-glucagon dynamics, as shown in our
previous study [18,20]. Section 7.1 in the Appendix ex-
plains how the DRNN model was selected over other
neural network architectures.
Fig. 1 depicts an overview of the system architecture
used to develop the DQN controllers evaluated on the
T1D in silico environment and to be potentially used in
clinical trials. Algorithm 1 and Algorithm 2 correspond
to the two-step learning framework in Section 2.2.
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Fig. 1: The system architecture to implement deep RL on T1D in the simulator (black arrows) and clinical trials
(red arrows).
2.1 Problem Formulation
The problem of basal glucose closed-loop control in
T1D can be formulated as an infinite-state Markov de-
cision process with noise, which is defined by a tuple
〈S,P, A,R, γ〉 consisting of a state S (i.e., physiologi-
cal state), a state transition function P , an actionA (i.e.,
insulin and glucagon control actions), a reward func-
tion R (i.e., glycemic outcomes), and a discount factor
γ ∈ [0, 1]. The agent in the environment takes an action
a ∈ A at each time step (i.e. each CGM measurement),
and then its state s ∈ S turns into the successor state
s′ according to P . The policy to select action for given
states is denoted by pi. Maximizing the accumulation
of expected reward rt = R(st, at) at each time step t is
the target of RL. An action-value (Q-function)Qpi(s, a)
can be defined to computed this reward:
Qpi(s, a) = E[
∞∑
t′=t
γt
′−trt′ |st = s, at = a, pi]. (1)
The optimal action-value function Q∗(s, a) =
maxpi Q
pi(s, a) offers the maximal values, which can
be determined by solving the Bellman equation defined
by
Q∗(s, a) = Es′
[
R(s, a) + γmax
a′
Q∗(s′, a′)
]
, (2)
The optimal action-value at the current state s is ob-
tained by selecting the action that maximizes expected
return with the optimal Q∗(s′, a′) at the next state s′.
Although this recursive equation can be estimated by
an iterative update, linear and non-linear approximators
are commonly used in RL for better generalization [24].
In this paper, DQNs are employed to approximate the
action-values Q(s, a; θ) ≈ Q∗(s, a) where θ represents
the parameters of the neural networks.
2.1.1 Agent states
In the closed-loop glucose control problem, we col-
lect the multi-modal data from the control system, as
shown in Fig. 1, to form a multi-dimensional input vec-
tor D to approximate physiological state S. Specifi-
cally, D comprises the real-time continuous blood glu-
cose levels G (mg/dL) measured with a CGM sensor,
the carbohydrate estimation of meal ingestion M (g)
recorder through a smartphone application, and hor-
mone doses delivered by the infusion pumps, includ-
ing the meal bolus insulin B, basal insulin Bas, and
glucagon dose C. Thus, we have D = {G,M, I, C} =
[dt+1−L, · · · , dt]T ∈ RL×4, where L is the length of
the time steps vector, I = B + Bas (Unit) represents
the sum of meal bolus insulin and basal insulin. The
approximated observation ot = st + et takes into ac-
count the errors or miss-estimations et in glucose mea-
surements G, carbohydrate meal estimation M , and the
meal insulin bolusB. HereB is computed fromM with
a standard bolus calculator [28]. From a deep RL per-
spective, the problem can be seen as an agent interacting
with an environment over sequential time steps. Every
five minutes, an observation ot can be obtained from the
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environment, and an action at can be taken according to
the agent’s policy.
2.1.2 Actions
Following the same framework, we provide two types
of delivery strategies for different pump settings. For
people with T1D wearing insulin pumps, the ac-
tion space is defined by modifying the basal insulin
rate (BR) as follows: {suspension of BR, 0.5*BR,
BR, 1,5*BR, 2*BR}. For those wearing dual-hormone
pumps, the action space is defined by the following op-
tions: {suspension of BR, 0.5*BR, BR, 1,5*BR, 2*BR,
delivering glucagon}. Note that the value of BR is
subject-specific and is known in advance. Based on pre-
vious works, we fix glucagon doses to 0.3 µg/kg for all
individuals and constraint the total amount of delivered
glucagon to a maximum of one mg per day [29].
2.1.3 Rewards
The desired performance of closed-loop glucose control
is to maintain BG in a target range of 70-180 mg/dL. By
using an empirical approached aiming at maximising
time in range (TIR) and minimising hypoglycemia, the
following piece-wise reward function was selected.
rt =

1, 90 ≤ Gt+1 ≤ 140
0.1, 70 ≤ Gt+1 < 90 & 140 < Gt+1 ≤ 180
−0.4− (Gt+1 − 180)/200, 180 < Gt+1 ≤ 300
−0.6 + (Gt+1 − 70)/100, 30 ≤ Gt+1 < 70
−1, else.
(3)
As depicted in Fig. 2, the agent receives a positive re-
ward if the BG level for the next state is in the target
range and a negative reward otherwise. If the BG is be-
low 30 mg/dL or above 300 mg/dL, we terminate ex-
ploration and restart the simulator. Different evaluated
reward functions are presented in Section 7.2 of the Ap-
pendix.
2.2 Two-step Learning Framework
First, we perform long-term generalized training to ob-
tain a population model for the hormone delivery strate-
gies. We use dilated recurrent neural networks [18] for
modeling the multi-dimensional time series including
glucose levels, hormone doses, and meal intake. Note
that other inputs affecting glucose levels, such as phys-
ical exercise, could also be considered. To train the
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Fig. 2: Visualization of the employed reward function
in terms of the glucose level (mg/dL) in the next state.
model, each basal hormone delivery (at five-minute in-
tervals) is regarded as an action taken by the agent,
while the glucose level on the next time step is set to
the reward by the criteria of time in range (Equation 3).
Secondly, by initializing the weights obtained from the
population model, we have a model with good initial
performance. With a transfer learning process, we indi-
vidualize the DQNs according to personal characteris-
tics and safety constraints with a small subject-specific
data-set.
During clinical trials, the data for training is usually
very limited, thus we aim at fast learning performance.
Therefore, we use a double DQN with modified impor-
tance sampling to further optimize approximated action
values. A state-of-art technique is employed to accel-
erate learning processes, where prioritized experience
replay samples important transitions more frequently
[30, 31]. To avoid overestimating the action values, a
double DQN decouples action selection and value eval-
uation by two separate neural networks [32], as shown
in Fig. 3. The second step is suitable for a clinical trial
setting, where the model is able to adjust itself in a rel-
atively short period of time.
2.3 Generalized DQN Training
In the first step, we use the simulator to generate an en-
vironment by using the average T1D subject for each
one of the virtual cohorts (i.e. adult and adolescent).
Compared to standard RNNs, DRNNs are preferred as
DQNs for learning the delivery strategies. The large re-
ceptive field brought by dilation is powerful to extract
features from glucose time series, where the dilated skip
connection can be represented as
c
(l)
t = f
(
n
(l)
t , c
(l)
t−d(l)
)
, (4)
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Fig. 3: The diagram of the propose double DQN. The
structure of the neural network is the same for both ac-
tion selection and value evaluation, which consists of an
input layer, a stack of DRNN layers, a fully-connected
(FC) layer and output. The input data includes BG se-
ries from CGM G, meal M , insulin I and glucagon C.
where c(l)t is the cell in layer l at time t, n
(l)
t is the input
to layer l at time t, d(l) denotes the dilation of layer l,
and f (·) represents the output function of RNN cells.
As shown in Fig. 3, we use three DRNN layers with
exponentially increasing dilation, to process the multi-
dimensional time-aligned sequence and extract high-
level features.. Then training is carried out in the simu-
lator with double DQN weights θ1, θ2, where action se-
lections θ1 and value evaluations θ2 are obtained from
two separate neural networks. According to Equation
(2), the action-selection networks are trained with the
loss as
JDQ(Q) = E(o,a,r,o′)∼ρ[(r+
γQ(o′, a′; θ2)−Q(o, a; θ1))2],
(5)
where ρ is a mini-batch with transitions
(o, a, r, o′) sampled from the memory pool, and
a′ = arg max′aQ(o
′, a′; θ1) is chosen by the action
selection DQN in Fig. 3. Thus, the Q-function can be
updated as
Qθ1(o, a)← Qθ1(o, a) + α(r+
γQθ2(o
′, arg maxaQθ1(o
′, a))−Qθ1(o, a)),
(6)
where α is the learning rate, and the weights of θ1 are
copied to θ2 with a fixed period. We optimize the learn-
ing rate by Adam method at each iteration [33]. The
corresponding pseudo-code is presented in Algorithm
1.
For each meal, a standard dose of bolus insulin is
delivered, and the agent explores random hormone de-
Algorithm 1 Generalized DQN Training
1: Input: the environment E with average T1D sub-
ject parameters Is provided by the simulator, up-
date period TG, ε-greedy
2: Initialize DQNs with random weights θ1, θ2, replay
memory B
3: for steps t∈ 1, 2, ..k do
4: Sample action from a ∼ pi(Qθ1 , ε), observe o′
in EIs, calculate r, store (o, a, r, o′) into B
5: end for
6: repeat
7: Sample action from a ∼ pi(Qθ1 , ε), observe o′
in EIs, calculate r, store (o, a, r, o′) into B
8: Sample a mini-batch uniformly from B and cal-
culate loss JDQ(Q)
9: Perform a gradient descent to update θ1
10: if t mod TG = 0 then θ2 ← θ1 end if
11: until converge
livery actions (single or dual) under policy pi that is ε-
greedy with respect toQθ1 . In this case, random actions
are tested with great flexibility and no safety concerns
since the simulator is employed for this purpose. Note
that some human intervention or demonstration at the
beginning of the RL process could potentially reduce
the training time slightly, but in our case, it was not
deemed necessary. At the end of this step, a general-
ized model consisting of a double DQN with weights
θ1 and θ2 is obtained.
2.4 Personalized DQN Training
After developing a generalized model, we fine-tune the
model by transfer learning with regards to the per-
sonal characteristic. We fetch the weights and features
from the generalized model, then train the personalized
DQNs within a data-set corresponding to a short pe-
riod of time with safety constraints. We can choose to
fine-tune all layers of the generalized model or to re-
tain the weights of some of the earlier layers and only
fine-tune a higher-level portion of the network to avoid
over-fitting. In experiments, we found that earlier layers
contain more generic features (e.g. insulin suspension
during the trend of hypoglycemia) that should be useful
for all the subjects with T1D.
Here a method modified from [31] is used for cal-
culating the loss of policy-generated data. Specifically,
Jn(Q) has an n-step returns (n= 12) to propagate val-
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ues of actions to earlier states rt + γri+1 + · · · +
γn−1ri+n−1 +maxaQ(oi+n, a), and JL2(Q) is an L2
regularization loss applied to θ to mitigate over-fitting.
Prioritized experience replay samples the transitions
with a probability Pri proportional to its importance
priority [30], which is computed from previous data and
normalized afterwards,
Pri =
pαi∑
i p
α
i
, pi = |δi|+ ′, (7)
where α ∈ [0, 1] determines the level of using prioriti-
zation, pi is the priority of transition i calculated from
last temporal-difference (TD) error δi and ′ is a small
positive constant. It allows the DQN to more frequently
replay transitions with higher TD error. In addition, to
ensure that hormones are delivered safely in the clinical
trial, constraints C are applied to the suggested action
before execution. Here we use a simple strategy for the
safety constraints: suspending basal insulin or glucagon
when the current BG level is below 80 mg/dL or over
160 mg/dL, respectively. In practice, the trend and pre-
diction of BG levels can also be used in the safety con-
straints for early interventions. With proper training of
the generalized model and adequate safety constraints,
this algorithm can be adopted in a clinical trial setting.
The corresponding pseudo-code detailing the algorithm
is presented in Algorithm 2.
3 Experiments
Following the architecture evaluation setup depicted in
Fig 1, we conducted experiments to evaluate, in silico,
the effectiveness of proposed deep RL framework with
the UVA/Padova T1D Simulator [27]. As stated in Sec-
tion 2.1.2, we use two settings of control actions in the
proposed deep RL (DRL) algorithm: single-hormone
(DRL-SH) and dual-hormone delivery (DRL-DH). Fol-
lowing a transfer learning strategy, we started with a
long-term exploration with 1,500 simulated days to ob-
tain a stable generalized model using Algorithm 1, then,
we performed personalized training for each individual
in the cohort (i.e. adult and adolescent) with 30 sim-
ulated days using Algorithm 2. Due to the significant
amount of data required, the generalized model is meant
to be trained in the simulator, whereas the personalized
model training has the potential to be done in a clinical
setting. Finally, the personalized models were tested in
a period of 90 days.
Algorithm 2 Personalized DQN Training
1: Input: replay memory B and DQNs weights θ′1, θ′2
from generalized training; individual environment
E, safety constraints C, update period TP , parame-
ter λ1, λ2,
2: Initialize personalized DQNs weights θ1 ← θ′1,
θ2 ← θ′2
3: Initialize replay memory D, merging B with prior-
ities
4: for steps i∈ 1, 2, ..N do
5: Sample action from policy a ∼ pi(Qθ1),
6: if a subject to C then execute a end if
7: Observe (o′, r) in E
8: Store (o, a, r, o′) in D, overwriting the samples
previously merged from B
9: Sample a mini-batch from D by modified im-
portance sampling Pr and update the transition pri-
ority
10: Calculate loss J(Q) = JDQ(Q) + λ1Jn(Q) +
λ2JL2(Q)
11: Perform a gradient descent to update θ1
12: if t mod TP = 0 then θ2 ← θ1 end if
13: end for
3.1 Experimental Setup
3.1.1 In Silico environment
The UVA/Padova T1D simulator provides an interac-
tive environment for the agent to explore and learn the
policy. We introduced additional intra-subject variabil-
ity in the meal protocol scenario and the parameters
of the T1D model [34]. In particular, we selected four
meals as the daily pattern (average cases: 7 am (70 g),
10 am (30 g), 2 pm (110 g), 9 pm (90 g)) with meal-
time variability (STD = 60 min) and meal-size vari-
ability (CV = 10%). The meal-duration was set to 15
minutes. A misestimation of carbohydrate amount be-
tween −30% and +10% with uniform distribution was
applied. Variability for meal absorption and carbohy-
drate bioavailability were set to 30% and 10%, respec-
tively. The variability of insulin sensitivity was consid-
ered to be 30% for adult cohort and 20% for adoles-
cent cohort, which are created by the scenario function
in the subjects’ own profile. These values of variability
were selected based on available physiological knowl-
edge and to achieve the glycemic outcomes commonly
observed in such populations when treated with stan-
dard therapy [35]. We saved intra-day and intra-person
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variability for each subject and used the same scenarios
for all the evaluated methods, i.e. same daily events and
variability time series, in order to have a fair compari-
son. We utilized the 10 virtual adults and 10 virtual ado-
lescents, plus the corresponding average subjects, for
generalized training.
3.1.2 Baseline method
As a baseline method, a low-glucose insulin suspension
(LGS) strategy, commonly found in sensor-augmented
insulin pumps, was employed [36]. LGS systems have
been proven to reduce hypoglycemia by suspending
basal insulin delivery [37]. For meal bolus calculation,
a standard bolus calculator was used [28].
3.2 Results
To evaluate the performance of the proposed algorithms
and compare them against the baseline method, we se-
lected five standard glycemic metrics commonly em-
ployed by the diabetes technology community [38].
These include: percentage time in the glucose target
range of [70, 180] mg/dL (TIR), percentage time below
70 mg/dL (i.e. hypoglycemia) (Hypo), percentage time
above 180 mg/dL (i.e. hyperglycemia) (Hyper), mean
BG levels (Mean), and risk index (RI). Results are ex-
pressed by mean values and standard deviations (mean
±SD).
Table 1 and Table 2 shows the results of the three
tested methods evaluated on the adult and adolescent
cohorts, respectively. Compared to LGS therapy, both
single-hormone and dual-hormone DRL models im-
prove the glucose control performance by reducing hy-
poglycemia, hyperglycemia and increasing TIR in the
two cohorts. Of note, the dual-hormone DRL model sig-
nificantly increases the mean TIR with a notable de-
crease of risk index, achieving the best performance.
Mean BG levels are maintained in the adult cohort,
while the improvement is significant in the adolescent
cohort.
For demonstration purposes, Fig. 4 graphically dis-
plays the performance of the three evaluated methods
for a chosen adult and a chosen adolescent over a three-
month testing period. In particular, the glucose pro-
file over 24 hours (mean ±SD) (i.e. ambulatory glu-
cose profile) and the control variability grid analysis
(CVGA), a commonly used tool for evaluating closed-
loop insulin delivery techniques, were employed [39].
Note that the displayed results in Fig. 4 are consistent
with the numerical results corresponding to the overall
population presented in Tables 1 and 2. Regarding the
CVGA, it is worth noting the significant improvement
achieved by DRL-DH when compared to LGS. In par-
ticular, the percentage of points in the A+B zones in-
creases from 26% to 94% for the adult cohort and from
27% to 76% for the adolescent cohort.
4 Discussion
4.1 Comparison with State-of-the-art
In the presented in silico experiments, when com-
pared against a low-glucose insulin suspension tech-
nique, the proposed methodology based on deep RL
achieves superior performance in terms of glycemic
outcomes. Comparing the proposed technique with ex-
isting closed-loop insulin delivery techniques, although
interesting, is a challenging task due to the difficulty in
replicating the testing scenarios and the tuning of the
controllers. Hence, a head-to-head comparison has not
been performed. However, although not directly com-
parable, an informal comparison with existing works
in the literature on RL for insulin and glucagon deliv-
ery has been done. In [40], the authors propose an RL-
based controller and achieve the adult TIR of 89% on
the UVA/Padova simulator, which is close to the perfor-
mance achieved by our DRL-DH model. Note that in
this previous work both basal and bolus insulin deliv-
ery are optimized, while in our work only basal insulin
delivery is optimized using different variability in the
simulator. In [41], Ngo and colleges use RL to optimize
control parameters in glycemic models without provid-
ing comparable TIR results. In a later paper [42], the
authors propose a DQNs algorithm to control insulin
delivery and they evaluate it on the previous version
of the UVA/Padova simulator. However, no comparable
glycemic outcomes are provided. Therefore, our work
not only proposes a novel deep RL algorithm for insulin
and glucagon delivery but also serves as a benchmark
for the future evaluation of other control algorithms. In
W3PHIAI-20 workshop [43], we briefly reported some
preliminary results corresponding to the dual-hormone
delivery configuration. In this paper, we extend this pre-
liminary work by developing a new model for single-
hormone delivery, improve the previous algorithms, use
more realistic scenarios, and introduce a new baseline
method for comparison purposes. To our knowledge,
this is the first study that systematically evaluates, in sil-
7
Table 1: The testing performance of glucose control on the adult virtual cohort
Method TIR (%) Hypo (%) Hyper (%) Mean (mg/dL) RI
LGS 77.55±6.78 2.87±1.38 19.58±5.79 140.78±8.23 2.52±0.89
DRL-SH 80.94±7.00∗ 2.06±1.33∗ 17.00±5.82 140.36±5.98 2.28±0.72
DRL-DH 85.55±7.33∗∗,† 1.92±1.90∗ 13.81±6.67∗∗,† 140.12±8.13 2.16±0.65†
Symbol ∗ indicates statistical significance (p ≤ 0.05 ) with with respect to the low-glucose suspension (LGS) and † indicates
statistical significance (p ≤ 0.05) with with respect to the single-hormone DRL (DRL-SH). A double symbol (e.g. ‡) indicates
statistical significance (p ≤ 0.01).
Table 2: The testing performance of glucose control on the adolescent virtual cohort
Method TIR (%) Hypo (%) Hyper (%) Mean (mg/dL) RI
LGS 55.50±14.68 6.93±4.69 37.57±11.64 162.15±20.46 4.76±2.70
DRL-SH 65.85±16.30∗∗ 5.51±3.37 28.63±14.36∗∗ 151.18±18.26∗∗ 3.99±2.43∗∗
DRL-DH 78.83±6.60∗∗,† 2.64±1.96∗∗,‡ 18.53±6.48∗∗,† 149.96±8.83∗∗ 2.94±0.99∗∗,‡
Symbol ∗ indicates statistical significance (p ≤ 0.05 ) with with respect to the low-glucose suspension (LGS) and † indicates
statistical significance (p ≤ 0.05) with with respect to the single-hormone DRL (DRL-SH). A double symbol (e.g. ‡) indicates
statistical significance (p ≤ 0.01).
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Fig. 4: Visualization of the experiment results for T1D subjects. (a) and (b): Performance of the three meth-
ods on an adult subject and an adolescent subject over the three-month testing period: (Top-to-bottom) LGS,
DRL-SH, DRL-DH, carbohydrate distribution. The average BG levels are shown in solid blue lines, and the
hypo/hyperglycemia thresholds are shown in dotted green/red lines. Blue shaded regions show the 95% confi-
dence interval (CI), and the purple shaded regions indicate the standard deviation. (c): The control variability grid
analysis (CVGA) plot for the adult (Top) and the adolescent (Bottom). The blue, orange and green dots represent
the LGS, DRL-SH and DRL-DH results, respectively.
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ico, a deep RL algorithm to control blood glucose levels
with single-hormone and dual-hormone delivery, using
the latest T1D simulator (2014 version) [27] and addi-
tional intra-subject variability.
4.2 Limitations and Future Work
Although the DQN models achieved superior control
performance in silico, clinical validation is still re-
quired. There are many uncertainties and perturbations
in real-world scenarios, and the main limitation of the
simulator is over-estimating the efficacy of glycemic in-
terventions. Therefore, in future work, we consider in-
corporating more data features that related to glucose
dynamics, including physical activities and health con-
ditions. Moreover, there is rapid development in deep
RL, and we plan to explore the latest advances in this
area, such as model-based RL [44], which have the po-
tential to further improve glycemic outcomes and ac-
celerate the training process. Following the proposed
setup and framework, it is convenient to implement
other deep RL techniques in basal glucose control.
4.3 Towards Clinical Trials
In the past years, the technological advances in the
field of diabetes technology and mobile phones have
increased the connectivity between mobile apps, CGM
and insulin pumps. As a result, many researchers have
integrated control algorithm (single-hormone and dual-
hormone) into apps to automatically administer or rec-
ommend hormone delivery and have evaluated them in
clinical trials [45–49] .
We have developed the deep RL models using Ten-
sorFlow, hence it is easy to implement such models on
smartphones, or embedded devices, by means of Ten-
sorFlow Lite converter. This has been previously done
by our group for implementing a DNN model on an app
for T1D management [17, 19]. This algorithm has the
potential to be continuously be trained and refined by
the new incoming data from devices (e.g. CGM, pump,
activity monitor) and user input (e.g. meals). There-
fore, the algorithm proposed in this work can be im-
plemented in a mobile app without much extra work
(Fig. 1).
5 Conclusion
With the aim of overcoming the challenge of blood glu-
cose control in T1D, we propose a novel deep RL algo-
rithm for optimizing basal insulin and glucagon deliv-
ery. Dilated RNNs are applied to the structure of double
DQNs to develop personalized models through a two-
step framework that involves transfer learning. When
compared to the baseline method with low-glucose in-
sulin suspension, the proposed methodology signifi-
cantly improves glycemic outcomes in a virtual adult
and adolescent population. This works shows that the
proposed approach has the potential to be adopted in a
clinical setting.
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7 Appendix
7.1 Neural Network Selection
Fig. 5 shows the TIR results achieved with the differ-
ent neural network architectures that we evaluated in
the experiments. Considering that the input data is a
multi-dimensional time-aligned sequence, we assumed
that an RNN-based model would be a good candidate to
map the multiple-step historical data. Therefore, we ex-
plored conventional long short-term memory (LSTM),
NNs with five fully-connected layers and DRNNs as
the potential structure of DQNs. The LSTM architec-
ture has recently achieved great success in time-aligned
tasks, but in our case, it obtains lower TIR results than
the DRNN. NNs are commonly used in DQNs as a basic
structure. However, the NN curve in Fig. 5 shows large
variability and lower mean TIR. Less variability indi-
cates a better capability to account for within-subject
variability. Thus, the NN structure was discarded. Re-
garding the DRNNs, the generalized model achieves a
good initial performance at the beginning of personal-
ized training. In addition, the DRNN curve has a pos-
itive trend and small variability, which indicates its ef-
fectiveness at adjusting the models for a specific subject
through a short period of time. Finally, DRNN predic-
tion models ranked top in Blood Glucose Level Predic-
9
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Fig. 5: TIR results (mean, 95% CI) corresponding to
DRL-DH during the personalized training for the adult
and adolescent cohorts. The blue, orange and green
lines show the results of DRNN, LSTM and NN mod-
els, respectively.
tion Challenge in 2018 [18]. Therefore, DRNNs was se-
lected as the DQNs for this work.
7.2 Reward Function
GL Range
(mg/dL)
Reward
Scheme 1
Reward
Scheme 2
Reward
Scheme 3
Reward
Scheme 4
0-30 -10 -1 -1 -1
30-70 -1 -0.5 −0.5 + GL−7080 −0.6 + GL−70100
70-90 +0.1 +0.1 +0.1 +0.1
90-140 +1 +1 +1 +1
140-180 +0.1 +0.1 +0.1 +0.1
180-300 -1 -0.5 −0.5− GL−180240 −0.4− GL−180200
300+ -10 -1 -1 -1
TIR Score (%) 75 88 86 93
Table 3: Reward functions and corresponding scores
Crafting reward functions for RL models is one of
the most crucial factors determining the model perfor-
mance. Note that this performance evaluation is only
applicable when the TIR score converges to a fixed
value through the training stage for the adult with Al-
gorithm 1 and dual-hormone. Different reward schemes
tested, together with their corresponding model scores,
can be seen in Table 3. In experiments, we started with a
piece-wise step function referred to as Reward Scheme
1, then we constrained the reward function range within
[-1, 1] to improve stability (Reward Scheme 2). Af-
terwards, we introduced slopes into the reward func-
tion to make the agent’s response to glucose changes
smoother (Reward Scheme 2). Note that the agent faces
an increasing penalty as glucose moves up in the hy-
perglycemic range, or down in the hypoglycemic range.
Finally, with minor adjustments on the slopes, the best
TIR score was obtained by Reward Scheme 4, where a
TIR of 93% can be achieved after 1.3 million training
steps.
7.3 Hyper-parameters
In Table 4, we list the hyper-parameters that have been
used in this work. For each parameter, we performed
limited tuning based on the state-of-art DQN [50]. All
the parameters are identical across all the virtual sub-
jects.
Parameter Value
Exploration before learning k 2000
Generalized network update period TG 1000
Generalized DQN ε-greedy 0.5→0.01
Personalized network update period TP 100
Discount factor γ 0.9
Adam learning rate 1× 10−5
Batch size 32
Number of time steps L 12
Replay buff size B 5000
Prioritization exponent α 0.3
Importance-sampling exponent β 0.4→1.0
Multi-step return λ1 0.1
L2 regularization λ2 1× 10−5
Cell type Vanilla RNN
DRNN dilation [1, 2, 4]
Hidden nodes of DRNN layers [32, 64, 128]
Table 4: List of hyperparameters
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